2023 ASCO Annual Meeting to Feature New Outcomes Research from Analysis Group
Event:2023 ASCO Annual Meeting
Dates:
June 2–6, 2023
Host:
American Society of Clinical Oncology (ASCO)
Location:
Chicago, IL, and online
Members of Analysis Group’s HEOR, Epidemiology & Market Access practice will present four posters at the 2023 ASCO Annual Meeting. The program will feature an extensive series of educational and scientific sessions on cancer research, treatment, and patient care.
Analysis Group poster presentations include:
“Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction (PCR) versus next-generation sequencing (NGS) testing strategies in metastatic non-small cell lung cancer (mNSCLC),” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice Presidents Bruno Émond and Marie-Hélène Lafeuille, Associate Laura Morrison, and Senior Research Professional Annalise Hilts – in collaboration with researchers from Janssen and The University of Chicago Medicine.
“Real-world (RW) dosing patterns and outcomes among chronic lymphocytic leukemia (CLL) patients (pts) with or without an ibrutinib (IBR) dose adjustment (DA) in first-line (1L),” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre and Vice Presidents Bruno Émond and Marie-Hélène Lafeuille – in collaboration with researchers from Janssen, The Ohio State University, and the Atrium Health Levine Cancer Institute.
“Indirect treatment comparison (ITC) of momelotinib (MMB) vs fedratinib (FED) safety in patients (pts) with myelofibrosis (MF),” coauthored by an Analysis Group team – including Managing Principal James Signorovitch, Vice President Gautam Sajeev, and Associates Sang Cho and Ryan Simpson – in collaboration with researchers from GSK, The University of Texas MD Anderson Cancer Center, the IRCCS Azienda Ospedaliero-Universitaria di Bologna, Wake Forest University School of Medicine, and Guy’s and St. Thomas’s NHS Foundation Trust.
“Efficacy and safety of first-line nivolumab plus relatlimab (NIVO + RELA) versus nivolumab plus ipilimumab (NIVO + IPI) in advanced melanoma: an indirect treatment comparison using patient-level data,” coauthored by an Analysis Group team – including Vice Presidents Viviana García-Horton and Jenny Zhou and Associate Yiqiao Xin – and researchers from Bristol Myers Squibb, the University of Essen and German Cancer Consortium, The University of Texas MD Anderson Cancer Center, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, the Dana-Farber Cancer Institute, Instituto Nazionale Tumori IRCCS Fondazione Pascale, the Royal Marsden NHS Foundation Trust, the University of Michigan Rogel Cancer Center, the Hôpital de la Timone, and the University of Sydney.